Trial Profile
An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Onvatilimab (Primary)
- Indications Cervical cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
- Sponsors Janssen Research & Development
- 24 Aug 2017 Status changed from recruiting to discontinued due to the Janssen business decision
- 23 Mar 2017 Planned End Date changed from 1 Oct 2018 to 23 Aug 2019.
- 22 Feb 2017 Planned number of patients changed from 150 to 124.